Research Papers:

Analysis of differential β variable region of T cell receptor expression and NAV3/TNFRSF1B gene mutation in mycosis fungoides

Hongzhou Cui, Jie Liu, Li Li, Jingyu Ren, Shuping Guo and Li Bai _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:17986-17990. https://doi.org/10.18632/oncotarget.7673

Metrics: PDF 754 views  |   HTML 998 views  |   ?  


Hongzhou Cui1,*, Jie Liu2,*, Li Li1, Jingyu Ren1, Shuping Guo1, Li Bai1

1Department of Dermatology, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China

2Jiangxi Provincial Center for Disease Control and Prevention, Nanchang, Jiangxi 330029, PR China

*These authors have contributed equally to this work

Correspondence to:

Li Bai, e-mail: baili@medmail.com.cn

Keywords: mycosis fungoides, T cell receptor beta, NAV3, TNFRSF1B

Received: October 16, 2015     Accepted: January 13, 2016     Published: February 24, 2016


Objective: This study aimed to analyze the predominant expression of the variable region of T cell receptor (TRBV) and determine whether NAV3 or TNFRSF1B gene mutation involved in the pathogenesis of MF.

Results: TRBV5-7 expression increased from the normal, early-stage to advanced-stage lesion in MF patient. By contrast, TRBV2 decreased with the lesion developed. We found no mutations of NAV3 or TNFRSF1B in the lesions from this study.

Materials and Methods: Real-time PCR were used to screen differential expression of TRBV in different lesions. Mutational analyses were used to validate genetic alterations in the skin lesions.

Conclusions: The identification of TRBV gene expression differences between normal and different stages of MF lesions provide insight into promising new diagnostic and prognostic biomarkers. None of the reported genetic abnormalities suggests complexity of progress from a primary cytogenetic event to an advanced stage with poor prognosis in MF.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7673